Cancer

Recruitment and enrollment of diverse participants representative of the general population are essential to gain meaningful insight into novel drug therapies. Oncological studies have been previously noted as lacking gender balance, which can result in skewed clinical trial results. This study, published in the Journal of Clinical Oncology, focuses on drug registration trials in particular,...

TUESDAY, Oct. 13, 2020 — There are considerable racial- and ethnicity-based cancer health disparities in the United States, according to a report published online Sept. 16 by the American Association for Cancer Research. John D. Carpten, Ph.D., from the University of Southern California in Los Angeles, and colleagues discussed cancer health disparities in the U.S....

The risk of prostate cancer is 75% higher in Black patients compared to white patients. Despite worse outcomes, Black patients are still underrepresented as research participants. A recent study not only found new genetic markets of prostate cancer risk but also identified a risk profile that can be applied across populations, emphasizing the value of...

Pooled relative risk of 0.988 for each increment of one cup of coffee per day revealed in meta-analysis of cohort studies Increased coffee consumption is associated with a reduced risk for prostate cancer, according to a review and meta-analysis published online Jan. 11 in BMJ Open. Xiaonan Chen, from Shengjing Hospital of China Medical University, and...

The risk of getting prostate cancer is 75% higher for Black men than it is for white men, and it is more than twice as deadly. Now, research is helping to bring genetic risks for people of various racial and ethnic groups into focus. In doing so, dozens more risk factors that could better help...

A multiple cohort study sponsored by the National Cancer Institute and Veterans Affairs Health System was conducted to determine if black men suffer at a higher prostate cancer mortality rate than non-Hispanic white men. Numerous trials have resulted in conflicting findings pertaining to the association between prostate mortality rate and association with other-cause mortality rates...

Participation rates similar for Black and White patients, treatment and cancer control trials More than half of patients offered participation in cancer clinical trials are willing to participate, according to a study published online Oct. 6 in the Journal of the National Cancer Institute to coincide with the ASCO Quality Care Symposium, held virtually from...

By Dr. Mark Abdelmalek and Lucien bruggeman At the onset of the novel coronavirus, American healthcare providers sought to limit non-essential in-person visits, opting instead to put off routine examinations – including annual cancer screenings – as part of an effort to curb risky face-to-face interactions. This precautionary approach was endorsed by the American Cancer Society,...

Transcriptional profiling identifies a gene program active in metastatic prostate cancers that failed to respond to enzalutamide treatment. Over the last decade, enzalutamide and similar drugs have led to significant tumor control and increased survival time for men who have metastatic prostate cancer that continues to grow despite treatments to reduce male hormone levels. About...